Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
futagliptin
- Development stage
- Phase 2
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Futagliptin is an oral small molecule drug that acts as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is being developed for the treatment of type 2 diabetes mellitus. As a DPP-4 inhibitor, futagliptin works by inhibiting the enzyme DPP-4, which results in increased levels of incretin hormones such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones help regulate blood glucose by increasing insulin secretion and decreasing glucagon release in response to meals, thereby improving glycemic control in patients with type 2 diabetes.
- Other names
- futagliptin benzoic acidfutagliptin benzoate
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on futagliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on futagliptin.